Utreloxastat (PTC857) is an oral small molecule with a unique mechanism of action that targets enzymatic activity in that pathway, and is being studied in the currently enrolling CARDINALS Phase 2 clinical trial to understand its potential therapeutic benefit in patients with ALS. A study overview given by Dr. Aaron Tansy and Dr. Jeremey Shefner.
